HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA’s Warning To Lash-Growth Firm Shows Risks In Third-Party Claims

This article was originally published in The Rose Sheet

Executive Summary

An April 18 FDA warning letter to Lifetech Resources LLC demonstrates that cosmetics firms will be held accountable when their websites feature third-party claims and testimonials that cross into drug marketing territory.

You may also be interested in...



European Commission Examining Prostaglandins In Cosmetics: Are They Safe? Are They Drugs?

Marketers of cosmetic products that rely on prostaglandins or their analogues to grow eyelashes – or compete against companies that use the ingredients – have until 22 October to submit information to the Commission, which will help inform an assessment by the Scientific Committee on Consumer Safety.

Interested In Using CBD Or Probiotics In Cosmetics? Ask Yourself Why – FDA’s Linda Katz

The answer to the ‘why’ question can help clarify whether a company is marketing a cosmetic or an unapproved drug, FDA’s cosmetics office director advised attendees at ICMAD’s 38th annual regulatory workshop in New York.

Rodan + Fields Concealed Prostaglandin Risks From Lash Boost Users – Class Action

Marketers of cosmetic lash enhancers that haven’t abandoned prostaglandin analogs in favor of peptides or botanical extracts should take heed of a proposed class action against Rodan + Fields in California’s Northern District. Plaintiffs say they would not have purchased the firm’s Lash Boost and suffered alleged adverse effects if they’d been properly informed about product risks.

Related Content

UsernamePublicRestriction

Register

LL1132972

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel